Literature DB >> 16150396

Management of recurrent cervical cancer.

G Dreyer1, L C Snyman, A Mouton, B G Lindeque.   

Abstract

Treatment for cervical cancer is very successful, especially in early stages. However, most patients presenting in late stages of disease will experience recurrence. The prognosis of recurrent disease is very poor and treatment options are limited. The diagnosis of recurrence may be apparent or difficult, but determining the extent of disease is always complex. Routine follow-up of asymptomatic patients has other objectives and is not a reliable way to detect recurrences. Symptomatic patients require extensive investigation to detect the extent of the disease. For patients with central pelvic recurrences, exenteration offers the prospect of survival in more than one-third of cases. Newer developments include laterally extended endopelvic resection that may become an option for patients with more extensive pelvic recurrence. For patients with recurrences of cervical cancer, the roles of second-time radiotherapy or postradiation chemotherapy are very limited. Palliative treatment is important for all patients with untreatable disease. Pain relief forms a central part of palliative care. Caregivers also experience emotional feelings and probably function best in a system offering strong colleageal support.

Entities:  

Mesh:

Year:  2005        PMID: 16150396     DOI: 10.1016/j.bpobgyn.2005.03.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  7 in total

Review 1.  Diagnosis and management of cervical cancer.

Authors:  Patrick Petignat; Michel Roy
Journal:  BMJ       Date:  2007-10-13

2.  E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway.

Authors:  Liangfang Shen; Shan Zeng; Jia Chen; Meizuo Zhong; Huixiang Yang; Ruojing Yao; Hong Shen
Journal:  Med Oncol       Date:  2007-09-28       Impact factor: 3.064

Review 3.  Cervical cancer and potential pharmacological treatment with snake venoms.

Authors:  Alejandro Montoya-Gómez; Leonel Montealegre-Sánchez; Herney Andrés García-Perdomo; Eliécer Jiménez-Charris
Journal:  Mol Biol Rep       Date:  2020-05-13       Impact factor: 2.742

4.  Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

Authors:  Myong Cheol Lim; Maria Lee; Seung Hyuk Shim; Eun Ji Nam; Jung Yun Lee; Hyun Jung Kim; Yoo Young Lee; Kwang Beom Lee; Jeong Yeol Park; Yun Hwan Kim; Kyung Do Ki; Yong Jung Song; Hyun Hoon Chung; Sunghoon Kim; Jeong Won Lee; Jae Weon Kim; Duk Soo Bae; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2017-03-15       Impact factor: 4.401

5.  FEZF1 is an Independent Predictive Factor for Recurrence and Promotes Cell Proliferation and Migration in Cervical Cancer.

Authors:  Yang Lan; Xuewei Xiao; Yu Luo; Zhengchi He; Xu Song
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

6.  Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer.

Authors:  Soo Jin Park; Jaehee Mun; Seungmee Lee; Yanlin Luo; Hyun Hoon Chung; Jae-Weon Kim; Noh Hyun Park; Yong Sang Song; Hee Seung Kim
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

Review 7.  Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective.

Authors:  Sarah Finocchario-Kessler; Catherine Wexler; May Maloba; Natabhona Mabachi; Florence Ndikum-Moffor; Elizabeth Bukusi
Journal:  BMC Womens Health       Date:  2016-06-04       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.